The Eosinophilia drugs in development market research report provides comprehensive information on the therapeutics under development for Eosinophilia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Eosinophilia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Eosinophilia and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Eosinophilia by eight companies/universities/institutes. The top development phase for Eosinophilia is phase ii with four drugs in that stage. The Eosinophilia pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Eosinophilia pipeline products market are: GSK, Shanghai Novamab Biopharmaceuticals and Nexeos Bio.
The key targets in the Eosinophilia pipeline products market include Interleukin 5, Interleukin 5 Receptor, and Interleukin 5 Receptor Subunit Alpha.
The key mechanisms of action in the Eosinophilia pipeline product include Interleukin 5 Inhibitor with three drugs in Phase III. The Eosinophilia pipeline products include six routes of administration with the top ROA being Subcutaneous and four key molecule types in the Eosinophilia pipeline products market including Monoclonal Antibody, and Small Molecule.
Eosinophilia overview
Eosinophilia is defined as an increase of circulating eosinophils. The count of eosinophilis may rise when there is an allergy, has certain infections, especially with parasites, or some types of leukemia.
For a complete picture of Eosinophilia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
